Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia

Yasmin Anum Mohd Yusof, M. L. Looi, A. H. Nor Aini, I. Merican, A. Wahidah, A. H. Mohd Radzi, A. Nor Azizah, N. H. Othman

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Transforming growth factor beta-1 (TGF-β-1) is a multifunctional cytokine involved in the regulation of growth and differentiation of both normal and transformed cells. The main aim of this study was to determine whether TGF-β-1 or alpha fetoprotein (AFP) or the combination of the two is a better indicator for hepatocellularcarcinoma (HCC). Serum TGF-β-1 and AFP were measured by ELISA in 40 healthy subjects, 23 patients with hepatocellular carcinoma (HCC), 70 patients with hepatitis B, 26 patients with hepatitis C and 16 patients with liver cirrhosis (LC). Patients with liver diseases showed significantly higher serum TGF-β-1 values (> 3 fold) compared to control subjects. As for serum AFP, significant elevation was only observed for HCC cases. Serum TGF-β-1 exhibited higher percent sensitivity compared to serum AFP in all liver diseases. Combination of serum TGF-β-1 and AFP increased specificities in all cases studied. In conclusion, serum TGF-β-1 is a more sensitive marker for HCC when compared to serum AFP and its specificity is increased when combined with serum AFP.

Original languageEnglish
Pages (from-to)223-227
Number of pages5
JournalMedical Journal of Malaysia
Volume64
Issue number3
Publication statusPublished - Sep 2009

Fingerprint

Transforming Growth Factor beta1
Transforming Growth Factor alpha
Malaysia
alpha-Fetoproteins
Liver Diseases
Hepatocellular Carcinoma
Chronic Disease
Transforming Growth Factor beta
Serum
Hepatitis C
Hepatitis B
Liver Cirrhosis
Healthy Volunteers
Enzyme-Linked Immunosorbent Assay
Cytokines

Keywords

  • AFP
  • Hepatocellular carcinoma
  • TGF-β-1
  • Tumour marker

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mohd Yusof, Y. A., Looi, M. L., Nor Aini, A. H., Merican, I., Wahidah, A., Mohd Radzi, A. H., ... Othman, N. H. (2009). Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia. Medical Journal of Malaysia, 64(3), 223-227.

Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia. / Mohd Yusof, Yasmin Anum; Looi, M. L.; Nor Aini, A. H.; Merican, I.; Wahidah, A.; Mohd Radzi, A. H.; Nor Azizah, A.; Othman, N. H.

In: Medical Journal of Malaysia, Vol. 64, No. 3, 09.2009, p. 223-227.

Research output: Contribution to journalArticle

Mohd Yusof, YA, Looi, ML, Nor Aini, AH, Merican, I, Wahidah, A, Mohd Radzi, AH, Nor Azizah, A & Othman, NH 2009, 'Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia', Medical Journal of Malaysia, vol. 64, no. 3, pp. 223-227.
Mohd Yusof, Yasmin Anum ; Looi, M. L. ; Nor Aini, A. H. ; Merican, I. ; Wahidah, A. ; Mohd Radzi, A. H. ; Nor Azizah, A. ; Othman, N. H. / Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia. In: Medical Journal of Malaysia. 2009 ; Vol. 64, No. 3. pp. 223-227.
@article{d5677ba2aac04c2495a905085e334672,
title = "Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia",
abstract = "Transforming growth factor beta-1 (TGF-β-1) is a multifunctional cytokine involved in the regulation of growth and differentiation of both normal and transformed cells. The main aim of this study was to determine whether TGF-β-1 or alpha fetoprotein (AFP) or the combination of the two is a better indicator for hepatocellularcarcinoma (HCC). Serum TGF-β-1 and AFP were measured by ELISA in 40 healthy subjects, 23 patients with hepatocellular carcinoma (HCC), 70 patients with hepatitis B, 26 patients with hepatitis C and 16 patients with liver cirrhosis (LC). Patients with liver diseases showed significantly higher serum TGF-β-1 values (> 3 fold) compared to control subjects. As for serum AFP, significant elevation was only observed for HCC cases. Serum TGF-β-1 exhibited higher percent sensitivity compared to serum AFP in all liver diseases. Combination of serum TGF-β-1 and AFP increased specificities in all cases studied. In conclusion, serum TGF-β-1 is a more sensitive marker for HCC when compared to serum AFP and its specificity is increased when combined with serum AFP.",
keywords = "AFP, Hepatocellular carcinoma, TGF-β-1, Tumour marker",
author = "{Mohd Yusof}, {Yasmin Anum} and Looi, {M. L.} and {Nor Aini}, {A. H.} and I. Merican and A. Wahidah and {Mohd Radzi}, {A. H.} and {Nor Azizah}, A. and Othman, {N. H.}",
year = "2009",
month = "9",
language = "English",
volume = "64",
pages = "223--227",
journal = "Medical Journal of Malaysia",
issn = "0300-5283",
publisher = "Malaysian Medical Association",
number = "3",

}

TY - JOUR

T1 - Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia

AU - Mohd Yusof, Yasmin Anum

AU - Looi, M. L.

AU - Nor Aini, A. H.

AU - Merican, I.

AU - Wahidah, A.

AU - Mohd Radzi, A. H.

AU - Nor Azizah, A.

AU - Othman, N. H.

PY - 2009/9

Y1 - 2009/9

N2 - Transforming growth factor beta-1 (TGF-β-1) is a multifunctional cytokine involved in the regulation of growth and differentiation of both normal and transformed cells. The main aim of this study was to determine whether TGF-β-1 or alpha fetoprotein (AFP) or the combination of the two is a better indicator for hepatocellularcarcinoma (HCC). Serum TGF-β-1 and AFP were measured by ELISA in 40 healthy subjects, 23 patients with hepatocellular carcinoma (HCC), 70 patients with hepatitis B, 26 patients with hepatitis C and 16 patients with liver cirrhosis (LC). Patients with liver diseases showed significantly higher serum TGF-β-1 values (> 3 fold) compared to control subjects. As for serum AFP, significant elevation was only observed for HCC cases. Serum TGF-β-1 exhibited higher percent sensitivity compared to serum AFP in all liver diseases. Combination of serum TGF-β-1 and AFP increased specificities in all cases studied. In conclusion, serum TGF-β-1 is a more sensitive marker for HCC when compared to serum AFP and its specificity is increased when combined with serum AFP.

AB - Transforming growth factor beta-1 (TGF-β-1) is a multifunctional cytokine involved in the regulation of growth and differentiation of both normal and transformed cells. The main aim of this study was to determine whether TGF-β-1 or alpha fetoprotein (AFP) or the combination of the two is a better indicator for hepatocellularcarcinoma (HCC). Serum TGF-β-1 and AFP were measured by ELISA in 40 healthy subjects, 23 patients with hepatocellular carcinoma (HCC), 70 patients with hepatitis B, 26 patients with hepatitis C and 16 patients with liver cirrhosis (LC). Patients with liver diseases showed significantly higher serum TGF-β-1 values (> 3 fold) compared to control subjects. As for serum AFP, significant elevation was only observed for HCC cases. Serum TGF-β-1 exhibited higher percent sensitivity compared to serum AFP in all liver diseases. Combination of serum TGF-β-1 and AFP increased specificities in all cases studied. In conclusion, serum TGF-β-1 is a more sensitive marker for HCC when compared to serum AFP and its specificity is increased when combined with serum AFP.

KW - AFP

KW - Hepatocellular carcinoma

KW - TGF-β-1

KW - Tumour marker

UR - http://www.scopus.com/inward/record.url?scp=77649123407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649123407&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 223

EP - 227

JO - Medical Journal of Malaysia

JF - Medical Journal of Malaysia

SN - 0300-5283

IS - 3

ER -